头孢呋辛
医学
眼内炎
白内障手术
外科
入射(几何)
置信区间
相对风险
前瞻性队列研究
眼科
抗生素
内科学
生物
微生物学
光学
物理
作者
M.C. García-Sáenz,Alfonso Arias Puente,Gil Rodríguez‐Caravaca,J. Bañuelos Bañuelos
出处
期刊:Journal of Cataract and Refractive Surgery
[Ovid Technologies (Wolters Kluwer)]
日期:2010-02-01
卷期号:36 (2): 203-207
被引量:115
标识
DOI:10.1016/j.jcrs.2009.08.023
摘要
To determine the differences in the endophthalmitis rates in cataract surgery before and after prophylactic use of intracameral cefuroxime.University Hospital Fundación Alcorcón, Madrid, Spain.This prospective study evaluated patients who had cataract surgery at a university eye center over a 10-year period (1999 to 2008). Since the protocol's approval by the Hospital Board in October 2005 to the end of the 10-year period, cataract patients were routinely treated with prophylactic intracameral cefuroxime. A database was used to measure the occurrence of endophthalmitis postoperatively. Then, the incidence of endophthalmitis before and after generalized use of prophylactic cefuroxime was compared. The effect of cefuroxime was evaluated by the relative risk.From January 1999 to December 2008, 13 652 patients had cataract surgery. Forty-two cases of postoperative bacterial endophthalmitis were reported. The endophthalmitis rate was 0.30% (95% confidence interval [CI], 0.26%-0.35%) overall, 0.59% (95% CI, 0.50%-0.70%) from January 1999 to September 2005, and 0.043% (95% CI, 0.02%-0.06%) from October 2005 to December 2008. The relative risk was 0.07 (range 0.022 to 0.231; P<.05).Intracameral cefuroxime proved to be effective in reducing the risk for acute-onset endophthalmitis after cataract surgery.
科研通智能强力驱动
Strongly Powered by AbleSci AI